Abstract
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease. Today, AD affects millions of people worldwide and the number of AD cases will increase with increased life expectancy. The AD brain is marked by severe neurodegeneration like the loss of synapses and neurons, atrophy and depletion of neurotransmitter systems in the hippocampus and cerebral cortex. Recent findings suggest that these pathological changes are causally induced by mitochondrial dysfunction, increased oxidative stress and elevated apoptosis. Until now, AD cannot be diagnosed by a valid clinical method or a biomarker before the disease has progressed so far that dementia is present. Furthermore, no valid method is available to determine which patient with mild cognitive impairment (MCI) will progress to AD. Therefore, a correct diagnosis in the early stage of AD is not only of importance considering that early drag treatment is more effective but also that the psychological burden of the patients and relatives could be decreased. In this review, we discuss the potential role of elevated apoptosis, increased oxidative stress and mitochondrial dysfunction as biomarker for AD in a peripheral cell model, the lymphocytes.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
Abdul HM, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA (2006) Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1–42), H2O2 and kainic acid: implications for Alzhei-mer’s disease. 1 Neurochem 96: 1322–1335
Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR (1998) The expression of key oxidative stress-han-dling genes in different brain regions in Alzheimer’s disease. J Mol Neurosci 11: 151–164
Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzhei-mer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161: 41–54
Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23: 298–304
Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L (2003) Time sequence of matu-ration of dystrophic neuntes associated with A beta deposits in APP/ PS1 transgenic mice. Exp Neurol 184: 247–263
Blass JP, Gibson GE, Hoyer S (2002) The role of the metabolic lesion in Alzheimer’s disease. J Alzheimers Dis 4: 225–232
Borroni B, DiLuca M, Padovani A (2006) Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? Eur J Pharmacol 545: 73–80
Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, Solaini G (2002) Cytochrome c oxidase and mito-chondrial F1FO-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease. Neurobiol Aging 23: 371–376
Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochon-drial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57: 695–703
Butterfield DA, Aksenov M, Markesbery WR (2001) Altered expression of cytochrome c oxidase and NADH dehydrogenase in Alzheimer’s disease brain: implications for oxidative stress and neurodegeneration. 1 Neurochem 77: 16
Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR (2004) Cytochrome c oxidase is decreased in Alzheimer’s disease platelets. Neurobiol Aging 25: 105–110
Casademont J, Miro O, Rodriguez-Santiago B, Viedma P, Blesa R, Cardellach F (2003) Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer’s disease. J Neurol Sci 206: 23–26
Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G (2002) Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer’s patients. Free Radic Biol Med 33: 1372–1379
Cecchi C, Latorraca S, Sorbi S, Iantomasi T, Favilli F, Vincenzini MT, Liguri G (1999) Gluthatione level is altered in lymphoblasts from pa-tients with familial Alzheimer’s disease. Neurosci Lett 275: 152–154
Culmsee C, Landshamer S (2006) Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr Alzheimer Res 3: 269–283
David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, Ravid R, Drose S, Brandt U, Muller WE, Eckert A, Gotz J (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L Tau transgenic mice. J Biol Chem 280: 23802–23814
DeLeo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, Filippini V, Galeotti T, Masullo C (1998) Oxidative stress and overexpression of manganese Superoxide dismutase in patients with Alzheimer’s disease. Neurosci Lett 250: 173–176
Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011–6018
Drouet M, Lauthier F, Charmes JP, Sauvage P, Ratinaud MH (1999) Age-associated changes in mitochondrial parameters on peripheral human lymphocytes. Exp Gerontol 34: 843–852
Eckert A, Cotman CW, Zerfass R, Hennerici M, Muller WE (1998) Lymphocytes as cell model to study apoptosis in Alzheimer’s disease: vulnerability to programmed cell death appears to be altered. J Neural Transm 259–267
Eckert A, Oster M, Zerfass R, Hennerici M, Muller WE (2001a) Elevated levels of fragmented DNA nucleosomes in native and activated lym-phocytes indicate an enhanced sensitivity to apoptosis in sporadic Alzheimer’s disease-Specific differences to vascular dementia. Dement Geriatr Cogn 12: 98–105
Eckert A, Schindowski K, Leutner S, Luckhaus C, Touchet N, Czech C, Muller WE (2001b) Alzheimer’s disease-like alterations in pe-ripheral cells from presenilin-1 transgenic mice. Neurobiol Dis 8: 331–342
Eckert A, Steiner B, Marques C, Leutz S, Romig H, Haass C, Muller WE (2001d) Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 64: 183–192
Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K, Muller WE (2003) Mitochondrial dysfunction, apoptotic cell death, and Alzhei-mer’s disease. Biochem Pharmacol 66: 1627–1634
Ferris SH, Yan B (2003) Differential diagnosis and clinical assessment of patients with severe Alzheimer disease. Alz Dis Assoc Dis 17Suppl 3: S92–S95
Frey C, Bonert A, Kratzsch T, Rexroth G, Rosch W, Muller-Spahn F, Maurer K, Muller WE, Eckert A (2006) Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer’s disease. J Neural Transm 113: 1753–1761
Frisoni GB, Padovani A, Wahlund LO (2004) The predementia diagnosis of Alzheimer disease. Alz Dis Assoc Dis 18: 51–53
Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, Mattson MP (1997) Alzheimer’s presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: Involvement of calcium and oxyradicals. J Neurosci 17: 4212–4222
Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Muller WE (2006) Mitochondrial dysfunction in sporadic and genetic Alzheimer’s dis-ease. Exp Gerontol 41: 668–673
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PLR, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 21: 3017–3023
Hoyer S (2000) Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35: 1363–1372
Huang HM, Fowler C, Xu H, Zhang H, Gibson GE (2005) Mitochondrial function in fibroblasts with aging in culture and/or Alzheimer’s disease. Neurobiol Aging 26: 839–848
Huang YD (2006) Apolipoprotein E and Alzheimer disease. Neurology 66: S79–S85
Ilic TV, Jovanovic M, Jovicic A, Tomovic M (1999) Oxidative stress indicators are elevated in de novo Parkinson’s disease patients. Funct Neurol 14: 141–147
Jellinger KA (2006) Challenges in neuronal apoptosis. Curr Alzheimer Res 3: 377–391
Kadioglu E, Sardas S, Asian S, Isik E, Esat KA (2004) Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer’s disease. Biomarkers 9: 203–209
Keil U, Bonert A, Marques CA, Scherping I, Weyermann J Strosznajder JB, Muller-Spahn F, Haass C, Czech C, Pradier L, Muller WE, Eckert A (2004) Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 279: 50310–50320
Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y (2002) Systemic increase of oxidative nucleic acid damage in Parkinson’s disease and multiple system atrophy. Neurobiol Dis 9: 244–248
Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac’h-Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, Pillot T (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J 19: 85–87
Leutner S, Schindowski K, Frolich L, Maurer K, Kratzsch T, Eckert A, Muller WE (2005) Enhanced ROS-generation in lymphocytes from Alzheimer’s patients. Pharmacopsychiatry 38: 312–315
Leutz S, Steiner B, Marques CA, Haass C, M’ller WE, Eckert A (2002) Reduction of trophic support enhances apoptosis in PC12 cells express-ing Alzheimer’s APP mutation and sensitizes cells to staurosporine-induced cell death. J Mol Neurosci 18: 189–201
Lombardi VR, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R (2004) Association between APOE epsilon4 allele and increased expression of CD95 on T cells from patients with Alzheimer’s disease. Method Find Exp Clin 26: 523–529
Malaplate-Armand C, Florent-Bechard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide path-way. Neurobiol Dis 23: 178–189
Mancuso M, Filosto M, Bosetti F, Ceravolo R, Rocchi A, Tognoni G, Manca ML, Solaini G, Siciliano G, Murri L (2003) Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer dis-ease. Exp Neurol 182: 421–426
Marques CA, Keil U, Bonert A, Steiner B, Haass C, Muller WE, Eckert A (2003) Neurotoxic mechanisms caused by the Alzheimer’s disease-linked Swedish amyloid precursor protein mutation-Oxidative stress, caspases, and the JNK pathway. J Biol Chem 278: 28294–28302
Martin MA, Molina JA, Jimenez-Jimenez FJ, Benito-Leon J, Orti-Pareja M, Campos Y, Arenas J (1996) Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson’s disease patients. Grupo-Centro de Trastornos del Movimiento. Neu-rology 46: 1343–1346
Mattson MP (2002) Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer’s disease. J Neurovirol 8: 539–550
Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430: 631–639
Maurer I, Zierz S, Moller HJ (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21: 455–462
Mecocci P, Cherubini A, Senin U (1997) Increased oxidative damage in lymphocytes of Alzheimer’s disease patients. J Am Geriatr Soc 45: 1536–1537
Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF (2002) Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 59: 794–798
Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005a) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer’s disease and in other neurodegenerative diseases. Neurobiol Aging 26: 587–595
Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, Siciliano G (2005b) Oxidative DNA damage in pe-ripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26: 567–573
Molina JA, deBustos F, JimenezJimenez FJ, BenitoLeon J, Gasalla T, OrtiPareja M, Vela L, Bermejo F, Martin MA, Campos Y, Arenas J (1997) Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer’s disease. Neurology 48: 636–638
Morocz M, Kaiman J, Juhasz A, Sinko I, McGlynn AP, Downes CS, Janka Z, Rasko I (2002) Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer’s disease. Neurobiol Aging 23: 47–53
Murray IVJ, Sindoni ME, Axelsen PH (2005) Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry 44: 12606–12613
Parker WD Jr (1991) Cytochrome oxidase deficiency in Alzheimer’s disease. Ann NY Acad Sci 640: 59–64
Parker WD Jr, Parks J, Filley CM, Kleinschmidt-DeMasters BK (1994) Electron transport chain defects in Alzheimer’s disease brain. Neurol-ogy 44: 1090–1096
Parshad R, Sanford KK, Price FM, Melnick LK, Nee LE, Schapiro MB, Tarone RE, Robbins JH (1996) Fluorescent light-induced chromatid breaks distinguish Alzheimer disease cells from normal cells in tissue culture. Proc Nat Acad Sci USA 93: 5146–5150
Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA (2000) Oxidative damage in Alzheimer’s disease: the metabolic dimension. Int J Devel Neurosci 18: 417–421
Petrozzi L, Lucetti C, Scarpato R, Gambaccini G, Trippi F, Bernardini S, Del Dotto P, Migliore L, Bonuccelli U (2002) Cytogenetic alterations in lymphocytes of Alzheimer’s disease and Parkinson’s disease patients. Neurol Sci 23Suppl 2: S97–S98
Rodriguez-Santiago B, Nunes V (2005) Expression of mitochondrial genes and transcription estimation in different brain areas in Alzheimer’s disease patients. Neurobiol Dis 18: 296–304
Schindowski K, Leutner S, Muller WE, Eckert A (2000) Age-related changes of apoptotic cell death in human lymphocytes. Neurobiol Aging 21: 661–670
Schindowski K, Frohlich L, Maurer K, Muller WE, Eckert A (2002) Age-related impairment of human T lymphocytes’ activation: specific differences between CD4(+) and CD8(+) subsets. Mech Ageing Dev 123: 375–390
Schindowski K, Kratzsch T, Peters J, Steiner B, Leutner S, Touchet N, Maurer K, Czech C, Pradier L, Frolich L, Muller WE, Eckert A (2003) Impact of aging: sporadic, and genetic risk factors on vul-nerability to apoptosis in Alzheimer’s disease. Neuromol Med 4: 161–178
Schindowski K, Peters J, Gorriz C, Schramm U, Weinandi T, Leutner S, Maurer K, Frolich L, Muller WE, Eckert A (2006) Apoptosis of CD4+ T and natural killer cells in Alzheimer’s disease. Pharmacopsychiatry 39: 220–228
Schuessel K, Schafer S, Bayer TA, Czech C, Pradier L, Muller-Spahn F, Muller WE, Eckert A (2005) Impaired Cu/Zn-SOD activity contri-butes to increased oxidative damage in APP transgenic mice. Neuro-biol Dis 18: 89–99
Schuessel K, Frey C, Jourdan C, Keil U, Weber CC, Muller-Spahn F, Muller WE, Eckert A (2006) Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radie Biol Med 40: 850–862
Selkoe DJ (2004) Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Int Med 140: 627–638
Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC, Malorni W (2005) Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: A pilot study. FEBS Lett 579: 2759–2766
Tacconi S, Perri R, Balestrieri E, Grelli S, Bernardini S, Annichiarico R, Mastino A, Caltagirone C, Macchi B (2004) Increased caspase activa-tion in peripheral blood mononuclear cells of patients with Alzhei-mer’s disease. Exp Nephrol 190: 254–262
Turner RS (2006) Alzheimer’s disease. Semin Neurol 26: 499–506
Wimo A, Winblad B, Aguero-Torres H, von Strauss E (2003) The mag-nitude of dementia occurrence in the world. Alz Dis Assoc Dis 17: 63–67
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag
About this paper
Cite this paper
Leuner, K. et al. (2007). Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer’s disease. In: Gerlach, M., Deckert, J., Double, K., Koutsilieri, E. (eds) Neuropsychiatric Disorders An Integrative Approach. Journal of Neural Transmission. Supplementa, vol 72. Springer, Vienna. https://doi.org/10.1007/978-3-211-73574-9_27
Download citation
DOI: https://doi.org/10.1007/978-3-211-73574-9_27
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-73573-2
Online ISBN: 978-3-211-73574-9
eBook Packages: MedicineMedicine (R0)